盘龙药业(002864) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was CNY 267,429,392.71, representing a 2.24% increase compared to the same period last year, and a total revenue of CNY 841,452,392.85 for the year-to-date, which is a 17.37% increase [4]. - The net profit attributable to shareholders for Q3 2025 was CNY 29,670,723.81, a decrease of 0.83% year-on-year, with a year-to-date net profit of CNY 89,805,874.28, reflecting a slight increase of 0.26% [4]. - The basic earnings per share for Q3 2025 remained unchanged at CNY 0.2800, with diluted earnings per share also at CNY 0.2800 [4]. - Total operating revenue for the current period reached ¥841,452,392.85, an increase of 17.4% compared to ¥716,922,919.85 in the previous period [17]. - Net profit for the current period was ¥89,602,427.86, slightly up from ¥89,282,648.59 in the previous period, reflecting a growth of 0.4% [18]. - The total comprehensive income for the current period was ¥89,602,427.86, compared to ¥89,282,648.59 in the previous period, reflecting a slight increase [18]. Assets and Liabilities - The total assets as of September 30, 2025, were CNY 2,401,032,519.70, marking a 5.31% increase from the end of the previous year [4]. - The company's total current assets amount to ¥1,876,878,524.25, an increase from ¥1,771,523,291.39 at the beginning of the period [15]. - Total liabilities rose to ¥715,314,034.47, up from ¥642,840,255.08, indicating an increase of 11.3% [17]. - The equity attributable to shareholders of the parent company increased to ¥1,683,956,206.54 from ¥1,635,217,029.35, a growth of 3.0% [17]. Cash Flow - The cash flow from operating activities for the year-to-date was CNY 89,155,948.33, showing a significant decrease of 30.54% compared to the previous year [4]. - Operating cash inflow for the current period was CNY 907,591,251.68, an increase of 11.06% from CNY 817,203,487.55 in the previous period [19]. - Net cash flow from operating activities decreased to CNY 89,155,948.33, down 30.49% from CNY 128,348,938.51 in the previous period [19]. - Cash outflow from investing activities was CNY 48,091,241.43, a decrease of 40.83% compared to CNY 81,359,538.72 in the previous period [19]. - Net cash flow from financing activities decreased significantly to -CNY 46,093,434.63, compared to a positive CNY 13,171,875.50 in the previous period [20]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,868 [11]. - The largest shareholder, Xie Xiaolin, holds 34.99% of shares, totaling 37,189,932 shares [11]. - The total number of preferred shareholders with voting rights is 0, indicating no preferred shares outstanding [11]. - The company has not reported any significant changes in its major shareholders or their shareholding status [12]. Operational Metrics - The company's prepayments increased significantly by 609.58% to CNY 41,211,947.04, primarily due to increased advance payments for goods [8]. - The company's long-term borrowings were reclassified, resulting in a 7455.14% increase in current liabilities due within one year, totaling CNY 98,881,724.13 [8]. - The revenue from traditional Chinese medicine products increased, contributing to a year-on-year revenue growth of 17.37% [9]. - The company reported a 45.27% increase in operating costs, amounting to CNY 398,130,242.64, attributed to the rise in sales volume of traditional Chinese medicine products [9]. - Research and development expenses for the current period were ¥24,095,842.41, slightly up from ¥23,846,304.90 in the previous period [17].